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linmuno-effector characteristics of peritoneal cells during CAPD treat-
ment: A longitudinal study. Peritoneal cells (PC) from 75 patients were
immuno-phenotypically and functionally characterized during the first
year of CAPD treatment (PCcapd) and compared to PC obtained by
laparoscopy of healthy women (control peritoneal cells). Patients were
divided, according to their peritonitis incidence (P1), into a high P1
(HPI) and a low P1 group (LPI). The yield of PCcapd decreased
significantly over the year. The differential cell count and immunophe-
notype of PCcapd remained unchanged in the LPI group, but the
percentage of macrophages decreased over the year in the HPI group.
Macrophages in the PCcapd, when compared to control peritoneal
cells, had a less mature phenotype as measured by RFD7 expression
but a higher Fc-receptor expression. The PCcapd showed a higher
percentage of B cells, CD4 positive T cells and activated T cells bearing
HLA-DRIDQ when compared to the control peritoneal cells. Over the
year a decrease in chemotactic activity of the PCcapd towards lO- M
N-formylmethionyl-leucyl-phenylalanine and dialysis effluent was ob-
served in LPI patients but not in HPI patients. After one year of
treatment, a significantly higher percentage of phagocytosing macro-
phages in the PCcapd of HPI patients was found when compared to LPI
patients. During the year there was an increase of immunophagocytosis
of PCcapd independent of P1. In conclusion, the CAPD peritoneal
cellular immune system showed signs of both immaturity and activa-
tion. The decrease in the yield and in the chemotactic activity of
PCcapd suggests an adaptation to the chronic stimulus of the dialysis
fluid. The higher chernotactic and phagocytosing activity of the PCcapd
after one year of CAPD treatment indicate that the peritoneal cells of
HPI patients are more activated compared to LPI patients.
Peritoneal macrophages from CAPD patients have been
reported to be relatively immature cells [1, 2] when compared to
control peritoneal macrophages. Characteristics of CAPD pen-
toneal macrophages such as increased respiratory burst activ-
ity, increased Fc-receptor expression, morphology of peroxi-
dase staining pattern and increased killing of Candida albicans
blastospores also suggests that these cells are functionally
activated [1—5]. These studies on the immune system of the
CAPD peritoneal cavity are different in methodology and are
therefore difficult to compare. For instance, there are striking
differences in the reports on the percentage of macrophages in
the CAPD peritoneal cells, ranging from an average of 40% to
90% [1, 2]. Furthermore, most studies undertaken so far have
been cross sectional in design and do not account for the
possible confounding influence of duration of CAPD treatment
on the immunophenotype and functional aspects of the CAPD
peritoneal cells.
Both the immaturity and activity of the CAPD peritoneal cells
could have clinical implications. An immature, not well-orga-
nized immune system may contribute to an increased suscept-
ability to bacterial peritonitis.
A decreased secretion of fibronectin and IL-i, an increase in
prostaglandin E2 production and a decrease in bacterial killing
capacity of peritoneal macrophages have been related to a high
peritonitis incidence in CAPD patients [6, 7]. An activated
immune system could contribute to the fibrosis of the peritoneal
membrane and loss of ultrafiltration that is observed during long
term CAPD treatment via mediators such as IL-if3 and TNFa
[8-li].
Few studies have investigated the immunophenotype of the
peritoneal cells from CAPD patients in relation to peritonitis
incidence. Davies et al [1] showed a relation between a high
peritonitis incidence and low RFD7 (a maturation marker)
expression on peritoneal macrophages and a low expression of
HLA-DR on peritoneal lymphocytes. Two previous studies
showed a relation between a low percentage of mesothelial cells
(MC) and a high peritonitis incidence [5, 12].
The present study has been designed to study the following
questions: (1) is the CAPD peritoneal cellular immune system
immature or activated; (2) is this influenced by duration of
CAPD treatment; and (3) are the characteristics of the CAPD
peritoneal cellular immune system related to the incidence of
bacterial peritonitis.
For this purpose the cellular composition, immunopheno-
type, chemotaxis, Fc-receptor positivity and immunophagocy-
tosis of CAPD peritoneal cells were investigated during the first
year of CAPD treatment. The data were compared with perito-
neal cells obtained by laparoscopy of healthy women (control
peritoneal cells).
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Patient population
From January 1987 to September 1991, 75 CAPD patients
were studied. This was a random selection of the 101 patients
that had started CAPD in this period. Nineteen out of the 75
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Male/female
Age years
15—35
36—55
56—75
Underlying kidney disease
Chronic glomerulonephritis
Diabetes mellitus
Chronic pyelonephritis
Polycystic kidney disease
Obstructive uropathy
Hypertension
Various
Unknown
Catheter system
Standard
Disconnect
patients did not complete the first year of treatment; 5 patients
were transferred to hemodialysis, 4 patients had a kidney
transplantation and 10 patients died (one case related to perito-
nitis). The clinical data of the 75 patients are shown in Table 1.
Patients were divided into two groups according to their peri-
tonitis incidence (P1): a high P1 (HPI patients, P1> 1 episode a
year) and a low P1 (LPI patients, P1  1 episode a year) group.
The 19 patients who dropped out were treated with CAPD on
average for 6.0 months (median: 6.0, range: 2.0 to 10.0). Their
median P1 (calculated as number of peritonitis episodes per
patient/month) did not differ significantly from the 56 other
patients.
Cell populations
Peritoneal cells were obtained from the overnight dialysate
(dwell time 8 to 10 hr) effluent. The complete dialysate was
drained into 50 ml tubes (Greiner, Alphen aid Rijn, The Neth-
erlands) and cells were isolated by centrifugation at 200 x g for
10 minutes at 4°C. The supernatant was discarded, the cell
pellets combined and centrifuged at 200 X g for 10 minutes at
4°C. The cells were washed once in 50 ml RPMI 1640 and the
cell pellet resuspended in ito 2 ml immunoglobulin free aRPMI
(RPMI 1640 medium supplemented with 2 ma L-glutamine, 50
U/ml penicillin and 50 pg/ml streptomycin; Mycofarm, Delit,
The Netherlands), and 10% heat-inactivated immunoglobulin-
free fetal calf serum (Gibco, Bio-Cult, Irvine, UK) and kept on
ice until use. All patients used commercial dialysis fluid Di-
aneal' (Baxter) with various glucose concentrations. The pen-
toneal dialysis effluents (PDE's) were analyzed every two to
three months during the first year of treatment. All PDE's were
analyzed at least one month after an episode of peritonitis.
The pentoneal cells obtained from healthy women undergo-
ing laparoscopic sterilization were used as a control peritoneal
cells population. Patients with endometriosis, pelvic inflamma-
tory disease, or neoplasia were excluded because of reported
macrophage abnormalities [13]. Peritoneal fluid (10 to 15 ml)
was aspirated by gentle suction from the cul-de-sac and anterior
uterovesical compartment [2]. This procedure yielded a median
of 8.7 x 106 cells (range: 0.8 to 46.0 106 cells, Fig. 1).
All cell samples were counted in a BUrker counting chamber
and viability was always above 90%. Differential cell counts
were done on cytocentrifuge preparations stained with May-
Grtinwald Giemsa (MGG) and at least 200 cells were counted.
Peritonitis incidence (P1) was calculated as the number of
peritonitis episodes (peritoneal cell count> 100 x 106/liter and
more than 50% neutrophilic granulocytes) in the first year of
treatment. Micro-organisms were cultured from the peritonitis
pentoneal effluent as described previously [14]. The P1 was
calculated only in patients that had completed the first year of
treatment (N = 56). The median P1 was 1.0 (range, 0 to 5; mean,
1.2) peritonitis episodes per patient (Fig. 2).
Monoclonal antibodies
For the recognition of monocytes and macrophages mono-
clonal antibody (McAb) EBM-11 (pan macrophages marker,
Dakopatts, Glostrup, Denmark) [15, 16] and RFD7 (recognizing
mature macrophages; gift of Dr. L.W. Poulter) [17] were used.
Anti-CD22 (pan B cell marker; Dakopatts), anti-CD2 (pan T cell
marker; Central Laboratory of the Netherlands Red Cross
Blood Transfusion Service, Amsterdam, The Netherlands),
anti-CD8 (recognizing cytotoxic/suppressor T cells; Sanbio,
Uden, The Netherlands) and anti-CD4 (recognizing helper/
inducer T cells; Sanbio) were used to identify the different
subsets of lymphocytes. For the determination of the percent-
age of HLA-DRJDQ positive cells McAb produced by clone
9.3F10 (ATCC, Rockville, New York, USA) [18] was used.
Immunocytochemistry
Cytocentrifuge preparations of peritoneal cells were fixed in
phosphate buffered formalin/aceton, washed twice in phosphate
buffered saline with 0.5% bovine serum albumin (PBS+) and
incubated for 45 minutes with the different McAb's. After
washing twice in PBS+ they were incubated for 45 minutes with
horseradish peroxidase-conjugated rabbit anti-mouse IgG (Da-
kopatts) diluted in PBS+ with 1% pooled human serum. After
washing twice in PBS peroxidase activity was shown by incu-
bation with diaminobenzidinetetrahydrochloride (0.5 mg/mI,
DAB), imidazole (3.4 mg/ml) and H202 (0.03%). Control prep-
arations showed no staining with an irrelevant antibody. A
minimum of 200 cells were examined for the presence of the
different antigens.
Chemotaxis
Chemotaxis was performed in a 48-well microchemotaxis
chamber [19]. Twenty-five microliters of RPMI 1640 (control)
and 108 M N-formylmethionyl-leucyl-phenylalanine (FMLP)
in RPMI 1640 were placed in the wells of the bottom chamber.
A chemo-attractant has been shown in the peritoneal dialysis
effluent (PDE) but not in the fluid obtained by laparoscopy [20].
Therefore, the PDE from which the CAPD penitoneal cells were
obtained was also tested for its chemo-attractivity. A polycar-
bonate filter sheet (Nucleopore Inc., Cabin John, Maryland,
USA), polyvinylpyrrolidone-free (PVP-F), 10 pm thick and 8
sm pore size was placed over the wells. A PVP-F filter was
used to prevent dropping off of migrated peritoneal cells from
the lower filter surface [21]. Peritoneal cells adjusted to 2.0 x
iO cells/SO l aRPMI (RPM! 1640 medium supplemented with
2 mrvi L-glutamine, 50 U/mI penicillin and 50 g/m1 streptomy-
cm (Mycofarm, Delft, The Netherlands), and 10% heat-inacti-
vated fetal calf serum (Gibco, Bio-Cult, Irvine, UK) were added
to each top well and the chambers were incubated in moist air
Table 1. Clinical data of CAPD patients
Number of patients
41/34
15
23
37
17
12
5
7
3
13
8
10
51
24
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Fig. 2. The distribution of the number of peritonitis episodes per
patient in the first year of CAPD treatment (N = 56).
with 5% CO2 at 37°C for three hours. Each test was performed
in triplicate. After incubation, the chamber was disassembled
and the filter removed. Nonmigrated cells were wiped off and
the filter was fixed in methanol and stained with Coomassie
Brilliant Blue. The number of cells per 0.36 mm2 area was
counted manually using a scored eyepiece. For each well 25
areas were counted and the average used to determine the
Fig. 1. The total yield of CAPD peritoneal
cells (A) and the total yield of mesothelial
cells (B). The open symbols represent the high
peritonitis incidence group (N = 19) and the
closed symbols the low peritonitis incidence
group (N = 37). Male (•, 0) and female (•,
0) CAPD patients are shown separately in
Figure 2B. The dashed line represents the
laparoscopy cells.
number of migrated cells in the area available (8 mm2). The
values are expressed as the percentage of migrated cells of the
total number of cells in the upper well.
Freshly isolated monocytes were used as a standard cell
population. Peripheral blood mononuclear cells (PBMC) were
isolated on a Lymphoprep gradient (Nycomed, Oslo, Norway)
from 10 ml heparinized peripheral blood. Using a MGG staining
on a cytocentrifuge preparation the percentage of monocytes
was determined and the PBMC adjusted to 4.0 x i05 mono-
cytes/ml.
Detection of Fc-receptor and immunophagocytosis
The percentage of Fc-receptor-positive peritoneal cells was
determined by rosette formation with IgG-coated sheep red
blood cells ([IgG]SRBC) using routine procedures [221. SRBC
were washed and a 1.6% (vollvol) suspension of packed cells in
PBS+ was made and rabbit anti-SRBC IgG (Nordic, Tilburg,
The Netherlands) to a subhemagglutinating concentration
added. After incubation for 30 minutes at 37°C the SRBC were
washed twice and resuspended in IgG free aRPMI to a 1.6%
(vollvol) suspension. Two hundred microliters of [IgG]SRBC
(1:10 diluted) suspension was added to 200 1d of peritoneal cells
suspension (1 x 106/ml in IgG free aRPMI). After a short
centrifugation (for 5 mm at 50 g and 4°C) followed by a one hour
incubation at 4°C the percentage [IgG]SRBC binding peritoneal
cells was microscopically determinated. Binding by peritoneal
cells of three or more erythrocytes per cell was considered
positive.
Immunophagocytosis was performed by the addition of 25 1.d
of peritoneal cells suspension (1 x 107/ml in IgG free aRPMI) to
25 pJ of the [IgG}SRBC suspension. After one hour of incuba-
tion at 37°C the extracellular red cells were lysed osmotically,
and after washing of the peritoneal cells cytocentrifuge prepa-
rations were made and MGG stained. The percentage of phago-
cytosing macrophages and the number of [IgG]SRBC per
phagocytosing macrophages ([IgG}SRBC/macrophages) were
determined. The phagocytosis capacity was calculated as: yield
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Table 2. Micro-organisms isolated from the peritonitis effluent
Quarters of the year
Low peritonitis incidence High peritonitis incidence
1 2 3 4 Total 1 2 3 4 Total
Peritonitis episodes 7 3 4 2 16 18 10 15 11 54
Organism
Gram positive 6 2 3 1 12 14 9 10 10 43
S. epidermidis 4 1 3 1 9 7 7 6 6 26
S. aureus 2 1 — — 3 7 2 3 4 16
Micrococcus sp. — — — — — — — 1 — 1
Gram negative 1 1 1 1 4 2 2 3 1 8
Pseudomonas sp. — — — 1 1 1 1 — — 2
Streptococcus sp. I — — — 1 1 — 1 1 3
Kiebsiella sp. — — — — — — — 2 — 2
E.coli — 1 — — 1 — — — — —
Acinetobacter sp. — — 1 — — — — — — —
Citrobacter sp. — — — — — I — — 1
No organism cultured — — — — — — 1 2 3
of peritoneal cells x percentage of phagocytosing macrophages
)< [IgG]SRBC/macrophages.
Statistical analysis
All parameters were analyzed for their relation with duration
of CAPD and PT. The first year of CAPD treatment was divided
into quarters: 1 to 3 months, 4 to 6 months, 7 to 9 months and
10 to 12 months after starting CAPD. Data of all patients studied
were expressed as medians with the range for each study
quarter. Trend analysis was performed using unbalanced re-
peated measures models with structured covariance matrices
(BMDP Statistical Software) [23]. For comparing CAPD pen-
toneal cells with control pentoneal cells the Wilcoxon test for
unpaired data was used. Correlation between different param-
eters was analyzed using the Spearman rank correlation test.
Results
Patient population
Clinical parameters (Tables I and 2) were analyzed for their
correlation to all measured parameters. Women had a signifi-
cantly lower percentage and yield of MC in their effluent
compared to men at every quarter of the year (P < 0.03, Fig. 1).
The clinical data (including the isolated organism as shown in
Table 2) of the 56 patients who completed the first year of
treatment did not differ significantly between the two P1 groups.
The immunological parameters of the peritoneal cells of CAPD
patients without a peritonitis episode during the first year of
treatment were not statistically significant different from the
immunological parameters of the pentoneal cells of CAPD
patients with one peritonitis episode.
Yield of peritoneal cells and differential cell count
During the first year of CAPD treatment there was a gradual
decrease in the yield of CAPD peritoneal cells (from 16.4 x 106
to 10.7 x 106 cells; Fig. 1). In contrast to the control peritoneal
cells, the CAPD peritoneal cells showed a lower percentage of
macrophages throughout the year (P values 0.04, 0.06, 0.2 and
0.04 for each quarter, respectively) and MC comprised 1 to 2%
of the CAPD peritoneal cells. No MC were detectable in the
control peritoneal cells. The MC could be easily recognized as
round cells with a dark staining cytoplasm and large round
nuclei with easy visible nucleoli, as shown previously [12]. The
MC showed signs of a stimulated peritoneum, since many MC
had multiple nuclei, were irregular in size and often were lying
in large aggregates without a regular structure.
The differential cell count of peritoneal cells of HPI patients,
but not of LPI patients, showed an increasing trend for the
percentage of lymphocytes and a decreasing trend for the
percentage of macrophages (P <0.01, Fig. 3). The percentages
of granulocytes in HPI and LPI patients were similar and
remained unchanged over the year.
Immunophenotype
Macrophages. Macrophages in the CAPD peritoneal cells
and control peritoneal cells were strongly HLA-DRIDQ posi-
tive. The control peritoneal cells contained more EBM-11
positive cells (84.5%, range 46.5 to 93.0%) that had a higher
expression of RFD7 (3 1.5%, range 14.5 to 56.5%) when com-
pared to the CAPD peritoneal cells of both the LPI and HPI
patients (P < 0.01). A decreasing trend over the year of the
percentage of cells reactive for the macrophage marker EBM 11
was observed in HPI patients (P < 0.01, Fig. 4).
T cells. In general the CAPD peritoneal cells contained more
CD2 positive cells, but this difference was only statistically
significant in the first quarter (P = 0.03). Both cell populations
had a CD4/CD8 ratio below 1.5, but the CAPD peritoneal cells
contained a relatively higher percentage of CD4 positive T cells
(P < 0.01, 0.06, 0.13 and 0.03, respectively) that sometimes
exceeded the number of CD8 positive cells more than tenfold.
Therefore the CD4/CD8 ratio of the CAPD peritoneal cells was
generally higher, reaching a statistically significant difference in
the first (P = 0.04) and fourth quarter (P = 0.03). The percent-
age of HLA-DRJDQ positive cells exceeded the percentage of
macrophages plus the percentage of B cells. This confirmed the
observation of many CAPD peritoneal T lymphocytes bearing
HLA-DRJDQ [24]. The percentage of CD2, CD4, CD8 positive
lymphocytes showed no relation with the P1.
B cells. The control peritoneal cells contained very few B
cells as compared to the CAPD peritoneal cells (0.2% vs. 1.5%,
P < 0.01 for every quarter). The percentage of CD22 positive
lymphocytes showed no relation with the P1.
Chemotaxis
The percentages of CAPD peritoneal cells migrating to FMLP
(from 6.8% to 4.3%, P = 0.03) and PDE (from 7.4% to 5.3%, P
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Fig. 4. The percentages of CAPD peritoneal cells reactive with the dtferent monoclonal antibodies. The open symbols represent the high
peritonitis incidence group (N = 19) and the closed symbols the low peritonitis incidence group (N = 37). The dashed line represents the
laparoscopy cells.
= 0.02) decreased over the year in LPI patients (Fig. 5). The
difference in chemotactic response to FMLP between the two
P1 groups increased during the year and was statistically
significant in the fourth quarter (4.3% vs. 10.1%, P < 0.05). The
CAPD peritoneal cells of LPI patients tended to have a lower
response to FMLP than the control cells (P < 0.05 in the third
quarter). The chemotactic response of CAPD peritoneal cells
and control peritoneal cells to the control medium RPMI 1640
(median 2.5%) was similar but was not related to duration of
CAPD or P1. The percentage healthy donor monocytes migra-
ting to PDE was similar during the first (17.9 7.8%) and fourth
quarters (19.7 9.0%).
Fc-receptors and immunophagocytosis
The percentage of Fc-receptor positive cells (73.0%, range
24.5 to 95.5%) did not change during the first year of CAPD
treatment. There was no significant difference with the control
peritoneal cells but relatively more macrophages were present
in the control peritoneal cells. This implies that almost all
CAPD peritoneal macrophages showed Fc-receptor positivity
(irrespective of P1) and on average only 85% of the control
peritoneal macrophages (P = 0.04). In general the CAPD
peritoneal cells of HPI patients comprised a higher percentage
of phagocytosing macrophages compared to LPI patients. This
difference, however, was only significant in the last quarter of
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the year (45.8 vs. 33.9%, P = 0.04). The number of [IgG]SRBC
per phagocytosing CAPD peritoneal macrophage increased
over the year (from 2.2 to 2.6, P = 0.04) in a similar way for
both P1 groups. The number of [IgG]SRBC per phagocytosing
macrophages was closely related to the percentage of phagocy-
tosing macrophages (r = 0.55, P < 0,001), but not to the
percentage of Fc-receptor positive cells. The phagocytosis
capacity decreased during the year (from 10.1 to 8.2, P = 0.01)
but was similar to the phagocytosis capacity of the control cells
(8.1 [IgG]SRBC's x 10) in every quarter of the year. The
phagocytosis capacity was not related to the P1.
Discussion
In this study the peritoneal cellular immune system during the
first year of CAPD treatment was investigated and compared to
control peritoneal cells obtained by laparoscopy. Differences
between the CAPD peritoneal cells and control peritoneal cells
were found and marked changes related to duration of CAPD
and/or P1 were observed within this period. It should be
realized that two basic assumptions underly the interpretations
of the data from this study. First, it is assumed that the CAPD
peritoneal cells from the overnight dialysis period reflect the
actual immunological status of the peritoneal cavity during the
whole day. Second, it is assumed that the CAPD peritoneal
cells obtained from PDE reflect the total peritoneal cell popu-
lation. This latter assumption is supported by a limited number
of studies [25, 26] which suggest that a substantial population of
peritoneal cells adhered to the peritoneum does not exist, as
discussed by Holmes et al [27].
During the first year of CAPD treatment there was a gradual
decrease in the yield of peritoneal cells. This may go on beyond
the first year and stabilize at an average of 5 to 8 x 106 cells per
overnight effluent after two to three years [12, 14, 27]. The
decrease in CAPD peritoneal cells yield does not seem to be
caused by a decrease in the chemo-attractivity of the PDE,
since there was no decrease in the chemotaxis of healthy donor
monocytes to PDE from the first and the fourth quarter.
However, as dialysis fluid has been shown to cause an influx
and activation of macrophages in the rat peritoneal cavity [28],
it is proposed that the decrease in yield of CAPD peritoneal
cells over time probably reflects the adaptation of the peritoneal
cavity to the dialysis fluid by a mechanism still unknown.
In accordance with most studies [2, 3, 12, 14, 27, 29] the
peritoneal macrophage was the predominant cell in the CAPD
peritoneal cells and control peritoneal cells, although in some
patients repeatedly more than 50% lymphocytes could be found
in the CAPD peritoneal cells. The HPI patients had a significant
higher percentage of macrophages (judged on morphological
criteria and EBM1 1 positivity), especially during the first half
year of treatment. Taken together with the total yield of
peritoneal cells, there was also an absolute increase in pento-
neal macrophages in HPI patients compared to LPI patients.
This probably indicates a more stimulated peritoneal immune
system in the HPI patient group. Most of the HPI patients (14
from the 19) had a peritonitis episode in the first month after
starting CAPD, before their CAPD peritoneal cells had been
analyzed. Therefore it was not possible to distinguish between
cause and effect.
Mesothelial cells were only found in the CAPD peritoneal
cells. The fresh CAPD fluid is cytotoxic for MC in vitro [30] and
causes mesothelial hyperplasia after twice daily injection in the
rat peritoneal cavity [31]. This implies that also in humans the
mesothelium will be damaged during CAPD. Therefore the MC
in the PDE reflect the active regeneration of the mesothelium,
as has been discussed in a previous study [12]. This concept is
supported by the finding that no MC were present in the control
peritoneal cells. The importance of an intact mesothelium could
be the production of prostaglandins [32, 33] or the prevention of
bacterial adherence to submesothelial structures [34]. The
percentage and yield of MC in HPI patients tended to be lower
then in LPI patients but this difference did not reach statistical
significance. Therefore these observations partly support the
previous reports that showed a relation between a low yield or
percentage of MC and a high P1 [5, 12].
A high expression of HLA-DR/DQ was present on peritoneal
macrophages of CAPD patients as well as of healthy controls.
However, the CAPD peritoneal macrophages have a far better
antigen presenting capacity when compared to monocytes and
control peritoneal macrophages [24] indicating a functional
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activation of the CAPD macrophages. Expression of HLA-
DR/DQ was seen on all peritoneal macrophages irrespective of
a HP! or a LPI. The percentage of macrophages is increased in
HP! patients but this is not accompanied by a similar increase in
the percentage of HLA-DRJDQ positive cells, as is seen for
instance for the percentage of Fc-receptor positive cells. This
indicates, although indirectly, that the percentage HLA-DR/DQ
positive peritoneal lymphocytes in HPI patients is lowered
when compared to LPI patients and therefore confirms the
reported low percentage of HLA-DR positive peritoneal lym-
phocytes in HPI patients [1]. It has been suggested that this
characteristic could be caused by a decreased secretion of IL-i
by peritoneal macrophages in such patients [11] and has been
interpreted as evidence of a depressed peritoneal immune
system. In this study it is shown that HPI patients have a
general higher percentage of peritoneal macrophages, a higher
chemotactic activity towards FMLP and a higher percentage of
phagocytosing macrophages in the last quarter of the year (as
will be discussed below), when compared to LPI patients.
These observations indicate a more activated peritoneal im-
mune system in HPI patients.
The CAPD peritoneal lymphocytes clearly showed features
of an activated immune status by the presence of increased
numbers of MHC class II positive lymphocytes when compared
to control peritoneal cells. A decreased CD4/CD8 ratio (below
1.5) in comparison to the peritoneal blood is characteristic for
the normal and CAPD peritoneal cavity [35, 36]. A relative
increase of CD8 positive cells (T suppressor cells) over CD4
positive T cells (T helper cells) possibly plays an important role
in parts of the body where activation of the local immune
system is controlled [37]. The higher CD4/CD8 ratio in the
CAPD peritoneal cavity when compared to the normal perito-
neal cavity shows the relative increase of CD4 positive T cells
in the CAPD peritoneal cavity. This shift in balance also
indicates an activated CAPD peritoneal T cell system.
In the functional assays CAPD peritoneal cells only differed
from control peritoneal cells in their increased percentage of
Fc-receptor positive macrophages. In the rat peritoneal cavity
dialysis fluid increases the percentage of Fc-receptor positive
macrophages [28]. The finding of the relative higher percentage
Fc-receptor-positive CAPD peritoneal macrophages therefore
reflects a functional activation of the macrophages.
In contrast to others [2, 20], the results from the chemotaxis
assay in general showed a lowered chemotactic activity toward
FMLP for the CAPD peritoneal cells compared to the control
peritoneal cells. However, it is important to distinguish be-
tween the chemotactic activity of the CAPD peritoneal cells of
HP! and LPI patients, since the latter showed a lower response
to FMLP and to the PDE. This is in accordance with Holmes et
a! [27] who reported a higher expression of C5a and FMLP
receptors on the surface of peritoneal leukocytes of HPI pa-
tients, although this difference did not reach statistical signifi-
cance. The chemotactic response to the PDE or FMLP remains
at a high level for the CAPD peritoneal cells of HPI patients
throughout the year whereas it decreases in LPI patients. This
indicates that the peritoneal immune system stays at a higher
level of activation in HPI patients.
An increase of phagocytosis activity but no increase in
Fc-receptor positivity has been reported after an increase of
dwell time [22, 38]. In this study and the study of Goldstein et
a! [2] the monocytes showed a higher chemotactic activity
compared to the macrophages. Therefore the increase in the
number of [IgG]SRBC phagocytosed per phagocytosing macro-
phages and the decrease of chemotactic activity in of CAPD
peritoneal cells in LPI patients during the first year of CAPD
treatment seem to be caused by an increased functional matu-
ration stage of the CAPD peritoneal macrophages. However,
these changes were not accompanied by an increase in the low
percentage of RFD7 positive macrophages and the reasons for
an accelerated maturation are not clear.
Due to the increase in [IgG]SRBC per phagocytosing macro-
phages the phagocytosis capacity of CAPD peritoneal cells
changed little despite the sharp decrease in yield of CAPD
peritoneal cells, and stayed at the level of control peritoneal
cells. This is in accordance with our clinical experience with
CAPD patients that the P1 does not increase after prolonged
CAPD treatment [39]. An increased percentage of phagocytos-
ing macrophages in HPI patients was found in this study.
Whereas the CAPD peritoneal cells of LPI patients tended to
decrease the opposite was seen for HPI patients. This pattern is
very similar to what is shown for the chemotactic activity and
gives additional evidence to support the concept of a more
activated peritoneal immune system in HPI patients. It is clear
that this activation is not seen in every immunological param-
eter measured, and this could explain why others have not
reported any relation between P1 and immuno-effector func-
tions of CAPD peritoneal cells [40, 41].
In conclusion, the CAPD peritoneal cells have features of
both immaturity and activation when compared to control
peritoneal cells. Changes in the yield and functional character-
istics of CAPD peritoneal cells during the first year of CAPD
treatment indicate an adaptation of the peritoneal immune
system to an activating stimulus, perhaps caused by the dialysis
fluid. No defects in immuno-effector functions could be de-
tected in the CAPD peritoneal cells when compared to control
peritoneal cells. A high number of peritonitis episodes caused a
more activated peritoneal cellular immune system throughout
the first year of CAPD and no significant risk factors that may
contribute to a HPI could be identified.
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